--- title: "13:15 ET\n\t\t\t\n\t\t\t\n\t\t\t\tATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit" description: "Rosen Law Firm has filed a class action lawsuit on behalf of investors in Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) for securities fraud during the period from October 31, 2022, to August 2" type: "news" locale: "en" url: "https://longbridge.com/en/news/233735358.md" published_at: "2025-03-29T17:15:59.000Z" --- # 13:15 ET ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit > Rosen Law Firm has filed a class action lawsuit on behalf of investors in Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) for securities fraud during the period from October 31, 2022, to August 2, 2024. Investors may be entitled to compensation without upfront fees. The lawsuit alleges that Actinium made misleading statements regarding its Iomab-B Biologics License Application, which may not meet FDA guidelines. Interested investors can join the class action by contacting the firm before May 26, 2025. , /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025. So What: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case\_id=37511 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email \[email protected\] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Actinium's data from Sierra Trial was unlikely to satisfy the U.S. Food and Drug Administration's ("FDA") guidelines for the acceptance and approval of Actinium's Iomab-B Biologics License Application ("BLA"); (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival ("OS") that Actinium provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Actinium's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4) as a result, defendants' positive statements about Actinium's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Actinium class action, go to https://rosenlegal.com/submit-form/?case\_id=37511 https://rosenlegal.com/submit-form/?case\_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email \[email protected\] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 \[email protected\] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. ### Related Stocks - [ATNM.US - Actinium Pharma](https://longbridge.com/en/quote/ATNM.US.md) - [NVEC.US - NVE](https://longbridge.com/en/quote/NVEC.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Actinium 製藥公司將在 2026 年 AACR 年會上展示兩篇摘要 \| ATNM 股票新聞 | Actinium Pharmaceuticals, Inc.（紐約證券交易所代碼：ATNM）將在 2026 年 AACR 年會上展示兩項摘要，重點介紹其在腫瘤學領域的 ATNM-400 和 Actimab-A 項目。演講將於 2026 年 | [Link](https://longbridge.com/en/news/276125126.md) | | Madrigal 製藥｜8-K：2025 財年 Q4 營收 3.21 億美元超過預期 | | [Link](https://longbridge.com/en/news/276330350.md) | | Orange 預計到 2028 年有機現金流將實現兩位數增長，並提高股息 | Orange 預計到 2028 年實現兩位數的有機現金流增長；提高股息 | [Link](https://longbridge.com/en/news/276310740.md) | | 15:56 ETKD 投資者有機會主導由 The Rosen Law Firm 提起的 Kyndryl Holdings, Inc.證券欺詐訴訟 | 羅森律師事務所已代表在 2024 年 8 月 7 日至 2026 年 2 月 9 日期間購買了 Kyndryl Holdings, Inc.證券的投資者提起集體訴訟。訴訟指控 Kyndryl 在其財務報表和內部控制方面做出了虛假陳述，導致投 | [Link](https://longbridge.com/en/news/276166078.md) | | 17:53 ETARDT 投資者有機會主導 Ardent Health, Inc. 的證券欺詐訴訟 | 羅森律師事務所提醒在 2024 年 7 月 18 日至 2025 年 11 月 12 日期間購買了阿登特健康公司（NYSE: ARDT）證券的投資者，注意 2026 年 3 月 9 日的主要原告截止日期，以便參與證券欺詐訴訟。該事務所聲稱阿 | [Link](https://longbridge.com/en/news/276081275.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.